Literature DB >> 2828663

Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat.

J Hauber1, B R Cullen.   

Abstract

We used site-directed mutagenesis to delineate sequences within the human immunodeficiency virus type I (HIV-I) long terminal repeat (LTR) required for trans-activation by the viral tat gene product. We demonstrated that sequences 3' to LTR position +44 are dispensable for trans-activation but that almost all of the mutations tested located between positions -17 and +44 greatly reduced trans-activation at both the transcriptional and posttranscriptional levels. However, displacement of the HIV-I LTR trans-activation-responsive region (TAR) 3' by insertion of up to 32 base pairs between the LTR TATA box and cap site had little effect on trans-activation. An analysis of the DNase I hypersensitivity profile of the HIV-I LTR in transfected cultures suggested the presence of at least two DNase I-hypersensitive sites, including one which extends into the viral TAR element; however, neither of these sites appeared to be significantly affected by tat coexpression. These results allow more precise delineation of the sequences important for TAR function and suggest that the TAR may be recognized by a host-specific DNA-binding protein rather than by the tat protein directly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828663      PMCID: PMC253619          DOI: 10.1128/JVI.62.3.673-679.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

2.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

3.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

4.  Improved estimation of secondary structure in ribonucleic acids.

Authors:  I Tinoco; P N Borer; B Dengler; M D Levin; O C Uhlenbeck; D M Crothers; J Bralla
Journal:  Nat New Biol       Date:  1973-11-14

Review 5.  DNAase I-hypersensitive sites of chromatin.

Authors:  S C Elgin
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

Review 6.  Chromatin.

Authors:  T Igo-Kemenes; W Hörz; H G Zachau
Journal:  Annu Rev Biochem       Date:  1982       Impact factor: 23.643

7.  New M13 vectors for cloning.

Authors:  J Messing
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

8.  Alternative sets of DNase I-hypersensitive sites characterize the various functional states of the chicken lysozyme gene.

Authors:  H P Fritton; T Igo-Kemenes; J Nowock; U Strech-Jurk; M Theisen; A E Sippel
Journal:  Nature       Date:  1984 Sep 13-19       Impact factor: 49.962

9.  Nuclease-hypersensitive sites in the chromatin domain of the chicken lysozyme gene.

Authors:  H P Fritton; A E Sippel; T Igo-Kemenes
Journal:  Nucleic Acids Res       Date:  1983-06-11       Impact factor: 16.971

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  108 in total

1.  Effects of homology length in the repeat region on minus-strand DNA transfer and retroviral replication.

Authors:  Q Dang; W S Hu
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs.

Authors:  A M Trubetskoy; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

Review 4.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

5.  An adenosine at position 27 in the human immunodeficiency virus type 1 trans-activation response element is not critical for transcriptional or translational activation by Tat.

Authors:  A D Blanchard; R Powell; M Braddock; A J Kingsman; S M Kingsman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Click dimers to target HIV TAR RNA conformation.

Authors:  Sunil Kumar; Patrick Kellish; W Edward Robinson; Deyun Wang; Daniel H Appella; Dev P Arya
Journal:  Biochemistry       Date:  2012-03-09       Impact factor: 3.162

7.  Analysis of regulatory elements of the equine infectious anemia virus and caprine arthritis-encephalitis virus long terminal repeats.

Authors:  L Sherman; A Yaniv; H Lichtman-Pleban; S R Tronick; A Gazit
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization.

Authors:  S Endo; S Kubota; H Siomi; A Adachi; S Oroszlan; M Maki; M Hatanaka
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

9.  Functional analysis of the Tat trans activator of human immunodeficiency virus type 2.

Authors:  R Fenrick; M H Malim; J Hauber; S Y Le; J Maizel; B R Cullen
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA.

Authors:  A Gatignol; A Kumar; A Rabson; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.